NCT07122674 - 18F-Pentixafor PET in Hematologic Malignancies | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Hematological Malignancies

Interventions

DRUG

18F-Pentixafor

Patients with hematological malignancies receive 55 MBq/kg of 18F-Pentixafor intravenously followed by PET/CT or PET/MR after 60min of injection.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

First Affiliated Hospital of Zhejiang University

OTHER